drugset / Trial / NCT05182944
A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to observe and evaluate the efficacy and safety of camrelizumab combined with albumin paclitaxel and cisplatin as perioperative treatment of advanced esophageal squamous cell.
Timeline
- Start
- 2022-01-15
- Primary completion
- 2024-01-15
- Completion
- 2027-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Albumin paclitaxel | Unknown | 125 mg/m2 | Intravenous |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |